



HAL
open science

Beyond phenotype: The genomic heterogeneity of co-infecting *Mycobacterium abscessus* smooth and rough colony variants in cystic fibrosis patients

Ana Victoria Gutiérrez, Sophie Alexandra Baron, Feyrouz Sonia Sardi, Jamal Saad, Bérengère Coltey, Martine Reynaud-Gaubert, Michel Drancourt

► To cite this version:

Ana Victoria Gutiérrez, Sophie Alexandra Baron, Feyrouz Sonia Sardi, Jamal Saad, Bérengère Coltey, et al.. Beyond phenotype: The genomic heterogeneity of co-infecting *Mycobacterium abscessus* smooth and rough colony variants in cystic fibrosis patients. *Journal of Cystic Fibrosis*, 2021, 20 (3), pp.421-423. 10.1016/j.jcf.2021.02.002 . hal-03333959

HAL Id: hal-03333959

<https://amu.hal.science/hal-03333959>

Submitted on 13 Jun 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 **REVISED VERSION**

2 **Beyond phenotype: The genomic heterogeneity of co-infecting *Mycobacterium***
3 ***abscessus* smooth and rough colony variants in cystic fibrosis patients**

4

5 **Running title:** Heterogeneity in *M. abscessus* infection

6 Ana Victoria Gutiérrez^{1,2}, Sophie Alexandra Baron^{1,2}, Feyrouz Sonia Sardi^{1,2}, Jamal
7 Saad^{1,2}, Bérengère Coltey³, Martine Reynaud-Gaubert^{1,3}, Michel Drancourt^{1,2*}

8

9 ¹ Aix Marseille Univ., IRD, MEPHI, Marseille, France.

10 ² IHU Méditerranée Infection, Marseille, France.

11 ³ Department of Respiratory Diseases, Adult Cystic Fibrosis Centre, Lung Transplant
12 Team, University Hospital of Marseille, Marseille, France.

13 * Corresponding author: Michel Drancourt

14 IHU Méditerranée Infection, UMR MEPHI

15 19-21, Bd Jean Moulin 13005 Marseille, France. Tel: +33 (0)4 13 73 24 01 Fax: + 33

16 (0) 13 73 24 02. Email: michel.drancourt@univ-amu.fr

17 Major article:

18 Abstract Word Count: 148

19 Text Word Count: 1,363<1200

20 Number of References: 16<20

21 Number of Figures: 2<3

22 Number of Tables: 1

23

24 **Highlights**

- 25 • *Mycobacterium abscessus* is an opportunistic pathogen in cystic fibrosis patients
- 26 • Two unrelated CF patients were colonized with two rough/smooth colony variants
- 27 • WGS was used to identify the heterogenic isolates and determine resistance profile
- 28 • We identify novel SNPs in one patient that could be involved in S to R morphology
- 29 • Unexpectedly, one rough *M. abscessus* clone that did not lose glycopeptidolipids

30

31 **Summary**

32 Two unrelated cystic fibrosis patients were co-infected with *Mycobacterium*
33 *abscessus* smooth and rough phenotypes. Smooth *M. abscessus* is proposed as the
34 infecting form, and the subsequent loss of glycopeptidolipids in the host leads to a
35 rough phenotype. Whole-genome sequencing (WGS) diagnosed two different *M.*
36 *abscessus* strains in patient N°1 but only one strain in patient N°2. In patient N°1,
37 rough isolate had novel mutations potentially involved in smooth-to-rough
38 morphology changes. In patient N°2, four genes were present in only the smooth
39 isolate. In addition, we obtained different susceptibility profiles in the four clinical
40 isolates. We revealed a new paradigm describing a cystic fibrosis patient infected
41 with two different clones, including a rough isolate, and identifying a rough *M.*
42 *abscessus* clone that did not lose glycopeptidolipids. We propose WGS for the
43 identification of heterogenic isolates and genetic determinants of antimicrobial
44 resistance, which we believe will positively influence treatment prognosis.

45

46 **Key words:** *Mycobacterium abscessus*; cystic fibrosis; smooth variant; rough variant;
47 Whole genome sequencing

48 **1. INTRODUCTION**

49 *Mycobacterium abscessus* (*Mabs*) has emerged as one of the most difficult-to-
50 manage opportunistic pathogen responsible for pulmonary infections, especially in
51 cystic fibrosis (CF) patients [1]. *Mabs* exhibits smooth or rough colony morphotypes
52 characterized by the presence or absence of surface-associated glycopeptidolipids
53 (GPL), respectively. Within the GPL locus in *Mabs* (CIP104536T), the *MAB_4099c*
54 (*mmp1*), *MAB_4098c* (*mmp2*), *MAB_4097c* (*gap*), *MAB_4117c* (*mmpS4*), *MAB_4116c*
55 (*mmpL4a*) and *MAB_4115c* (*mmpL4b*) genes [2] have shown to play an important
56 role in the GPL production. Indels and SNPs in this locus have also been related to
57 the loss of production of GPL leading to rough morphotype in clinical isolates [3]. The
58 rough morphotype is associated with higher virulence and persistent infections [4] .
59 Previous studies have shown a low frequency of this mixed phenotype in *Mabs*
60 pulmonary infections and more recently seems to become a new concern due to
61 different resistance profiles between isolates [5,6]

62 Here, we describe two cases of respiratory tract co-infection with *Mabs*
63 smooth and rough phenotypes, in two unrelated CF patients. We used whole
64 genome sequencing (WGS) to precisely identify the isolates and describe potential
65 genetic differences associated with the clonality of smooth-to-rough transition.

66

67 **2. LABORATORY INVESTIGATIONS**

68 **2.1. *Mabs* isolates.**

69 A sputum sample collected in a 34-year-old CF patient N°1 yielded *Mabs* rough
70 colonies (P9527) and smooth colonies (P9528) (Figure 1; Supplementary Files). Both
71 isolates exhibited the same antibiotic susceptibility profile except for clarithromycin-

72 resistance in P9527 and clarithromycin-susceptibility in P9528 (Table 1). Further, a
73 sputum sample collected in a 25-year-old CF patient N°2, yielded *Mabs* rough
74 colonies (P9529) and smooth colonies (P9530) (Figure 1). P9529 exhibited a high-
75 resistant level to clarithromycin whereas we observed an inducible resistance to
76 clarithromycin at day 14 in P9530 isolate (Table 1).

77 **2.2. Lipid analysis.**

78 Apolar lipids were extracted from smooth and rough colonies of reference *Mabs*
79 CIP104536^T and from our four isolates and analysed by thin-layer chromatography
80 (TLC) as previously described [3]. Rough P9527 isolate lacked bands corresponding
81 to GPL whereas this lipid was surprisingly intact in rough P9529 isolate (Figure 2).

82 **2.3. WGS bioinformatic analysis.**

83 Illumina MiSeq sequences (Illumina Inc., San Diego, USA) were obtained in a paired-
84 end strategy, assembled using Spades [8] and annotated using Prokka [9]. Genome
85 sequences have been deposited into the EMI database under the following
86 accession numbers: P9527 (ERS3527803), P9528 (ERS3527804), P9529
87 (ERS3527805), and P9530 (ERS3527806). The Roary pipeline
88 ([https://usegalaxy.org.au./](https://usegalaxy.org.au/)) generated pangenome using default parameters. *In silico*
89 DNA-DNA hybridization yielded 94.6% identity between P9527 and P9528
90 suggesting that patient N°1 was infected by two different *Mabs* clones; and 99.8%
91 identity between P9529 and P9530 suggesting that patient N°2 may be infected by
92 one *Mabs* clone (Table S1). We calculated the single-nucleotide polymorphisms
93 (SNPs) distance of the four genomes identified 21,825/4,162,736-bp SNPs between
94 P9527 and P9528 but 1,313/4,162,736-bp between P9529 and P9530. In order to
95 genotypically associate the possible smooth-to-rough conversion in patient N°2,

96 SNPs were identified manually in the GPL locus using MUSCLE in Unipro UGENE
97 v1.32.0 [10] (Supplementary Files). Although no indels were detected, a comparison
98 between the smooth P9530 and rough P9529 strain identified a discrete amount of
99 nonsynonymous SNP (Table S2) including *mmpL4b* (A212C), *mps1* (C2369G), *mps2*
100 (A1400G, C1534G, G2041C, G6194T, G7534C) and *gap* (G11A, G50T). Using
101 Phandango online tool [9], four genes were found only in smooth isolates (Figure
102 S1). Nucleotide BLAST alignment showed the following: (1) a hypothetical protein
103 presenting a partial match with *MAB_3888* and corresponding to a putative RNA
104 polymerase sigma-70 factor, (2) a PE family immunomodulator, PE5, having a
105 complete match with *MAB_0046*, (3) a putative PPE family protein, PPE2, showing a
106 complete match with *MAB_0809c* and (4) a hypothetical protein presenting a partial
107 match with *MAB_4691c* and corresponding to a probable non-ribosomal peptide
108 synthetase PstA (Table S3). Further analysis was performed in another promising
109 area of the pangenome showing a differential pattern between the smooth and rough
110 morphotypes, however any genetic trait linked to a specific phenotype was observed.

111

112 **2.4. Genotypic characterization of *erm* (41) and *rrl* genes.**

113 None of the four clinical isolates had mutations at positions 2058 and 2059 in the *rrl*
114 gene [12]. As for the *erm*(41) gene [13,14], only P9528, which showed a
115 clarithromycin-sensitive phenotype, carried a non-functional Erm(41) (C28 sequevar),
116 while the three other isolates clarithromycin-resistant after 14-day incubation, were
117 identified as T28 sequevar. An additional mutation (V80I) found in all isolates (Table
118 S5), has been previously associated with clarithromycin resistance in Korea [10].

119 **3. DISCUSSION**

120 Smooth/rough mixed pulmonary infection are rarely reported in *Mabs* and *M. bolletii*
121 and never for *M. massiliense* [5]. In two CF patients here reported, *Mabs*
122 rough/smooth colony variants were firmly identified by WGS analysis.

123 Smooth non-cording and rough cording morphotype differences rely on the
124 presence/absence of GPL, respectively [12]. In *M. abscessus*, the *mmp1*, *mmp2*, *gap*,
125 *mmpS4*, *mmpL4a* and *mmpL4b* genes drive GPL production: A CG insertion in *mmp1*
126 arrests transcription of the *mmp1-mmp2-gap* operon [6]. Additional indels (insertions
127 and deletions) and SNPs in *mmp1*, *mmp2*, *gap*, *mmpS4*, *mmpL4a* and *mmpL4b* also
128 induce loss of production of GPL and a rough morphotype in clinical isolates [7].
129 Although these previously reported insertions were not found in P9527, this isolate
130 however harboured multiple novel SNPs potentially linked to GPL loss and rough
131 morphology. Moreover, a recent report explained the effect of aminoglycosides in the
132 smooth-to-rough transition in *Mabs* without depletion of GPL, cells exposed to
133 subinhibitory concentrations of amikacin showed a rough phenotype and an
134 increased expression of *MAB_3508c*, homologous to *M. tuberculosis whiB7*
135 responsible of mediate antibiotic resistance [13]. Patient N°2 was treated with
136 tobramycin, this may have influence in the smooth-to-rough transition of P9530 strain
137 which did not present any change in the GPL profile. A second GPL-like locus of two
138 non-ribosomal peptide synthase *pstA* genes (*MAB_4690c-MAB_4691c*) similar to
139 *mps1* and *mps2*, may be implicated in GPL production and the smooth-to-rough
140 transition [6]. Here, we identified four genes specific for the smooth clinical isolates,
141 one of them encoding a hypothetical protein homologous to *MAB_4691c*, opening the
142 possibility of new markers for the smooth-to-rough transition.

143 Our genetic analysis suggests colonization by two distinct strains in one patient,
144 while in the second patient, both the smooth and rough strains were closely related,

145 suggesting morphology conversion. It has been proposed that the smooth-to-rough
146 conversion occurs in the host by clonal diversification. In a follow-up study in patients
147 chronically infected with *Mabs*, initial isolation of the smooth morphotype and later
148 isolation of the rough morphotype was observed [7]; nevertheless, whether this event
149 could be due to initial colonization with smooth morphotype and a consequent re-
150 colonization with a secondary rough strain is not being considered. Despite having
151 multiple *ex vivo* and *in vivo* reports that relate the severity of the infection to
152 morphology [14], it is still not clear how this change from a smooth to rough
153 morphology could affect a patient's prognosis.

154 *Mabs* is a difficult-to-treat opportunistic pathogen and clarithromycin has been
155 used in monotherapy before description of inducible resistance to macrolides [14]. In
156 addition to acquired macrolide resistance conferred by mutated *rrl* gene encoding the
157 peptidyltransferase domain of the 23S rRNA, inducible resistance to macrolides
158 attributed to *erm(41)* was described; this methylase is proposed to monomethylate
159 adenine at position 2058 in the 23S rRNA, conferring resistance [15]. Loss of function
160 of *erm(41)* is linked to a clarithromycin-sensitive phenotype, as described for the
161 T28C mutation [16]. Here, we describe a patient coinfecting with two different *Mabs*
162 strains, P9527/P9528, each genotype concordant with the clarithromycin-
163 resistant/sensitive phenotype, respectively. This diversification can have implications
164 on the susceptibility profile, increasing the difficulty of selecting the proper therapy,
165 which could impact the disease outcome. Another unexplored possibility is co-
166 infection by multiple *M. abscessus* complex strains without differences in colony
167 morphology that go unnoticed.

168 We propose systematic WGS to guarantee the identification of different *Mabs*
169 isolates and their antibiotic susceptibility profile, to guide the most appropriate
170 treatment in CF patients.

171 Previous studies using *ex vivo* and *in vivo* models suggested that rough morphotype
172 exhibited increased virulence as compared to smooth morphotype,^{8,9} yet these
173 experimental observations poorly translated in clinical observations and the actual
174 characterization of clinical isolates. Such clinical isolates have not been genome
175 sequenced in order to more deeply interpret phenotypic data. Future studies could
176 focus on the influence of Whib7 on phenotype and antibiotic resistance.

177 **Acknowledgements**

178 This work was supported by the French Government under the « Investissements
179 d'avenir » (Investments for the Future) programme managed by the Agence
180 Nationale de la Recherche (ANR, fr: National Agency for Research), (reference:
181 Méditerranée Infection 10-IHU-03). This work was supported by the Région Le Sud
182 (Provence Alpes Côte d'Azur) and European funding FEDER PRIMMI.

183 **Transparency declaration**

184 MD is a co-founder and shareholder of the start-up Culture-Top that is cited in this
185 manuscript. The other authors declare that they have no competing interests.

186 **Authors' contributions**

187 SB and MDr designed the study and drafted and revised the manuscript.

188 MRG performed medical examinations.

189 AVG, FSS, and JS performed microbiology analyses.

190 AVG performed SNP identification on the GPL locus and *erm(41)* and *rrl* genes,
191 performed the lipid extraction and analysis, and wrote the paper.

192 JS performed the WGS and analyses.

193 All authors have read and approved the final manuscript.

194

195 **References**

- 196 1. Lopeman RC, Harrison J, Desai M, Cox JAG. Mycobacterium abscessus:
197 Environmental Bacterium Turned Clinical Nightmare. *Microorganisms*. **2019**;
198 7(3).
- 199 2. Ripoll F, Deshayes C, Pasek S, et al. Genomics of glycopeptidolipid
200 biosynthesis in Mycobacterium abscessus and *M. chelonae*. *BMC Genomics*.
201 **2007**; 8:114.
- 202 3. Park IK, Hsu AP, Tettelin H, et al. Clonal Diversification and Changes in Lipid
203 Traits and Colony Morphology in Mycobacterium abscessus Clinical Isolates. *J*
204 *Clin Microbiol*. **2015**; 53(11):3438–3447.
- 205 4. Pawlik A, Garnier G, Orgeur M, et al. Identification and characterization of the
206 genetic changes responsible for the characteristic smooth-to-rough morphotype
207 alterations of clinically persistent Mycobacterium abscessus. *Mol Microbiol*.
208 **2013**; 90(3):612–629.
- 209 5. Ruger K, Hampel A, Billig S, Rucker N, Suerbaum S, Bange F-C.
210 Characterization of rough and smooth morphotypes of Mycobacterium
211 abscessus isolates from clinical specimens. *J Clin Microbiol*. **2014**; 52(1):244–
212 250.
- 213 6. Shaw LP, Doyle RM, Kavaliunaite E, et al. Children With Cystic Fibrosis Are
214 Infected With Multiple Subpopulations of Mycobacterium abscessus With
215 Different Antimicrobial Resistance Profiles. *Clin Infect Dis*. **2019**; 69(10):1678–
216 1686.
- 217 7. Besra GS. Preparation of cell-wall fractions from mycobacteria. *Methods Mol*
218 *Biol*. **1998**; 101:91–107.
- 219 8. Bankevich A, Nurk S, Antipov D, et al. SPAdes: a new genome assembly
220 algorithm and its applications to single-cell sequencing. *J Comput Biol*. **2012**;
221 19(5):455–477.
- 222 9. Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics*. **2014**;
223 30(14):2068–2069.
- 224 10. Okonechnikov K, Golosova O, Fursov M, UGENE team. Unipro UGENE: a
225 unified bioinformatics toolkit. *Bioinformatics*. **2012**; 28(8):1166–1167.
- 226 11. Hadfield J, Croucher NJ, Goater RJ, Abudahab K, Aanensen DM, Harris SR.
227 Phandango: an interactive viewer for bacterial population genomics.
228 *Bioinformatics*. **2018**; 34(2):292–293.
- 229 12. Wallace RJ, Meier A, Brown BA, et al. Genetic basis for clarithromycin
230 resistance among isolates of Mycobacterium chelonae and Mycobacterium
231 abscessus. *Antimicrob Agents Chemother*. **1996**; 40(7):1676–1681.

- 232 13. Kim H-Y, Kim BJ, Kook Y, et al. Mycobacterium massiliense is differentiated
233 from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin
234 ribosome methyltransferase gene (erm) and clarithromycin susceptibility
235 patterns. Microbiol Immunol. **2010**; 54(6):347–353.
- 236 14. Bastian S, Veziris N, Roux A-L, et al. Assessment of clarithromycin susceptibility
237 in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl
238 sequencing. Antimicrob Agents Chemother. **2011**; 55(2):775–781.
- 239 15. Lee SH, Yoo HK, Kim SH, et al. The drug resistance profile of Mycobacterium
240 abscessus group strains from Korea. Ann Lab Med. **2014**; 34(1):31–37.
- 241 16. Howard ST, Rhoades E, Recht J, et al. Spontaneous reversion of
242 Mycobacterium abscessus from a smooth to a rough morphotype is associated
243 with reduced expression of glycopeptidolipid and reacquisition of an invasive
244 phenotype. Microbiology (Reading, Engl). **2006**; 152(Pt 6):1581–1590.
- 245 17. Tsai S-H, Lai H-C, Hu S-T. Subinhibitory Doses of Aminoglycoside Antibiotics
246 Induce Changes in the Phenotype of Mycobacterium abscessus. Antimicrob
247 Agents Chemother. **2015**; 59(10):6161–6169.
- 248 18. Bernut A, Herrmann J-L, Ordway D, Kremer L. The Diverse Cellular and Animal
249 Models to Decipher the Physiopathological Traits of Mycobacterium abscessus
250 Infection. Front Cell Infect Microbiol. **2017**; 7:100.
- 251 19. Mushatt DM, Witzig RS. Successful treatment of Mycobacterium abscessus
252 infections with multidrug regimens containing clarithromycin. Clin Infect Dis.
253 **1995**; 20(5):1441–1442.
- 254 20. Nash KA, Brown-Elliott BA, Wallace RJ. A novel gene, erm(41), confers
255 inducible macrolide resistance to clinical isolates of Mycobacterium abscessus
256 but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother.
257 **2009**; 53(4):1367–1376.
- 258 21. Bastian S, Veziris N, Roux A-L, et al. Assessment of clarithromycin susceptibility
259 in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl
260 sequencing. Antimicrob Agents Chemother. **2011**; 55(2):775–781.
- 261 22. Malcolm KC, Caceres SM, Pohl K, et al. Neutrophil killing of Mycobacterium
262 abscessus by intra- and extracellular mechanisms. PLoS ONE. **2018**;
263 13(4):e0196120.

264

265

266 Table 1. Results of broth microdilution susceptibility testing of the two morphotypes of
 267 each species. Minimum Inhibitory Concentration were interpreted using CLSI M24-2
 268 recommendations.

	P9527	P9528	P9529	P9530
Amikacin	16 (R)	32 (R)	16 (R)	32 (R)
Clarithromycin (D4)	16 (R)	0.25 (S)	16 (R)	0.5 (S)
Clarithromycin (D14)	>256 (R)	0.5 (S)	>256 (R)	4 (I)
Ofloxacin	16 (R)	16 (R)	8 (R)	>16 (R)
Bactrim	>16 (R)	>16 (R)	>16/304 (R)	32 (R)
Tigecycline	1 (S)	1 (S)	1 (S)	<1 (S)
Doxycycline	>16 (R)	>16 (R)	>16 (R)	>16 (R)

269 S, susceptible; R, resistant; I, intermediate. The results are expressed in $\mu\text{g}\cdot\text{mL}^{-1}$.

270

271 **Figure legends:**

272 **Figure 1.** Morphologic appearance of four clinical isolates of *M. abscessus* and
273 rough (R) and smooth (S) reference strains after 4-day incubation on Middlebrook
274 7H10 agar at 37°C.

275

276 **Figure 2.** Lipid profile of four *M. abscessus* isolates, showing the P9527 strain as the
277 only one with a deficient glycopeptidolipid (GPL) profile. Equal weights of total lipid
278 extracts from the *M. abscessus* smooth (Swt), rough (Rwt), P9527, P9528, P9529
279 and P9530 strains were analysed by thin-layer chromatography using
280 chloroform/methanol/water (9:10:1, v/v/v). GPLs are indicated with a black box.

281


282

283


Rwt



Swt




P9527



P9528



P9529



P9530



